Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

Background T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical practice for hematological malignancies, the absence of sufficient infiltrating T cells is a major barrier for efficacy in solid tumors. In t...

全面介紹

書目詳細資料

Principais autores:	Rob C Hoeben, Sjoerd H van der Burg, Thorbald van Hall, Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana A M Mustafa, Nadine van Montfoort
格式:	Artigo
語言:	Inglês
出版:	BMJ Publishing Group 2020-10-01
叢編:	Journal for ImmunoTherapy of Cancer
在線閱讀:	https://jitc.bmj.com/content/8/2/e001191.full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!